4 Undervalued Pharmaceuticals Stocks for Tuesday, October 01
Discover the top 4 undervalued Pharmaceuticals stocks for Tuesday, October 01 based on AAII’s Stock Grades.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Omar Beirat
Omar Beirat
Jack Gilleland
Jenna Brashear
Jenna Brashear
| Share Statistics | BAYRY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $61,528.0 | $449.3 | 94% |
|
| Shares Out (Mil) | 1,115.6 | 46.5 | 94% |
|
| Institutional Ownership | 50.0% | 80.9% | 30% |
|
| Float (Mil) | 982.4 | 46.8 | 91% |
|
| Beta | 0.81 | 0.73 | 47% |
|
| Avg Daily Volume (000s) | 1,308 | 319 | 72% |
|
| Price Change (52-week) |
98.0% | 54.2% | 95% |
|
| Growth | BAYRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 1.1% | 6.1% | 21% |
|
| Net Income (5yr) | 19.8% | (1.6%) | 73% |
|
| EPS (5yr) | 19.8% | 15.0% | 68 |
|
| Dividends (5yr) | (44.5%) | 0.0% | 57% |
|
| Cash Flow (5yr) | (13.8%) | (15.1%) | 55% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 2 | 2 | |
| Current EPS | na | $1.312 | $1.366 | |
| Month Ago EPS | na | $5.022 | $5.348 | |
| # Rev Up | na | 0 | 0 | |
| # Rev Down | na | 1 | 0 | |
| Three Months Ago EPS | na | $4.983 | $5.269 | |
| Year/Year Chg | na | (130.3%) | (137.0%) | |
| Financials | BAYRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $51,974 | $303 | 97% |
|
| Net Income (TTM) (Mil) | ($1,643) | ($11) | 1% |
|
| EPS (TTM) | ($1.673) | ($0.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | $4,235 | ($7) | 94% |
|
| Net Cash Flow (TTM) (Mil) | $3,834 | $1 | 99% |
|
| Long-Term Debt (Q1) (Mil) | $42,814 | $6 | 98% |
|
| Enterprise Value (Q1) (Mil) | $101,720 | $458 | 96% |
|
| Valuation | BAYRY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.18 | na |
|
| P/E | na | 22.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | BAYRY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 59.4% | 69.5% | 72% |
|
| Net Margin | (3.2%) | 3.9% | 26% |
|
| ROA | (1.3%) | (23.8%) | 35% |
|
| ROE | (4.8%) | (25.9%) | 30% |
|
| Liabilities to Assets | 71.5% | 31.6% | 67% |
|
| F-Score | na | 3 | na |
|
Bayer Aktiengesellschaft did not pass any screens on 11/12/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors